Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples